Trial · NCT02697734
Results by group385
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 385
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Randomized Participants With a Complete Response | Osilodrostat Group | 37 | Participants | ||
| Percentage of Randomized Participants With a Complete Response | Osilodrostat Placebo Group | 2 | Participants | ||
| Percentage of Participants With mUFC ≤ ULN at Week 36 | All Participants Combined | 80.8 | 95% Confidence Interval 69.9 to 89.1 | Percentage of participants | |
| Change From Baseline in mUFC | Osilodrostat Group | actual - baseline | 421.4 | Standard Deviation 291.25 | nmol/24hr |
| Change From Baseline in mUFC | Osilodrostat Placebo Group | actual - baseline | 451.5 | Standard Deviation 535.09 | nmol/24hr |
| Change From Baseline in mUFC | Osilodrostat Group | change from baseline at week 2 (n=47,24) | -139.3 | Standard Deviation 404.45 | nmol/24hr |
| Change From Baseline in mUFC | Osilodrostat Placebo Group | change from baseline at week 2 (n=47,24) | 164.9 | Standard Deviation 543.82 | nmol/24hr |
| Change From Baseline in mUFC | Osilodrostat Group | change from baseline at week 5 (n=46,25) | -252.8 | Standard Deviation 338.48 | nmol/24hr |
| Change From Baseline in mUFC | Osilodrostat Placebo Group | change from baseline at week 5 (n=46,25) | -37.3 | Standard Deviation 280.84 | nmol/24hr |
| Change From Baseline in mUFC | Osilodrostat Group | change from baseline at week 8 (n=44,25) | -330.2 | Standard Deviation 303.35 | nmol/24hr |
| Change From Baseline in mUFC | Osilodrostat Placebo Group | change from baseline at week 8 (n=44,25) | -35.0 | Standard Deviation 325.30 | nmol/24hr |
| Change From Baseline in mUFC | Osilodrostat Group | change from baseline at week 12 (n=44,24) | -332.7 | Standard Deviation 315.50 | nmol/24hr |
| Change From Baseline in mUFC | Osilodrostat Placebo Group | change from baseline at week 12 (n=44,24) | -49.1 | Standard Deviation 332.29 | nmol/24hr |
| Change From Baseline in mUFC | Osilodrostat Group | change from baseline at week 14 (n=45,25) | -191.7 | Standard Deviation 446.77 | nmol/24hr |
| Change From Baseline in mUFC | Osilodrostat Placebo Group | change from baseline at week 14 (n=45,25) | -209.5 | Standard Deviation 407.62 | nmol/24hr |
| Change From Baseline in mUFC | Osilodrostat Group | change from baseline at week 17 (n=45,25) | -238.8 | Standard Deviation 362.46 | nmol/24hr |
| Change From Baseline in mUFC | Osilodrostat Placebo Group | change from baseline at week 17 (n=45,25) | -284.5 | Standard Deviation 557.47 | nmol/24hr |
| Change From Baseline in mUFC | Osilodrostat Group | change from baseline at week 20 (n=44,24) | -294.5 | Standard Deviation 316.65 | nmol/24hr |
| Change From Baseline in mUFC | Osilodrostat Placebo Group | change from baseline at week 20 (n=44,24) | -355.1 | Standard Deviation 538.96 | nmol/24hr |
| Change From Baseline in mUFC | Osilodrostat Group | change from baseline at week 23 (n=44,25) | -314.1 | Standard Deviation 307.60 | nmol/24hr |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02697734/results